Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. reported earnings results for the nine months ended September 30, 2024. For the nine months, the company reported sales was CNY 820.39 million compared to CNY 653.79 million a year ago. Revenue was CNY 820.39 million compared to CNY 653.79 million a year ago.
Net income was CNY 182.59 million compared to CNY 141.34 million a year ago. Basic earnings per share from continuing operations was CNY 0.4385 compared to CNY 0.3373 a year ago. Diluted earnings per share from continuing operations was CNY 0.4385 compared to CNY 0.3373 a year ago.
Shandong Bailong Chuangyuan Bio-Tech Co Ltd is a China-based company mainly engaged in food additives. The Company's main businesses include prebiotic series products, mainly including fructooligosaccharides, isomalt oligosaccharides, galacto-oligosaccharides, xylo-oligosaccharides; dietary fiber series products, mainly including resistant dextrin and polydextrose; other starch sugar (alcohol) products, mainly including maltitol, fructose syrup, and maltose syrup; and healthy sweetener products, mainly for the research and development, production and sales of allulose. The Company's main products are widely used in food, dairy products, infant milk powder, functional beverages, health care products, medicine, animal nutrition and feed industries.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
